aid: iambic-tx
name: Iambic Therapeutics
description: >-
  Iambic Therapeutics is a San Diego, California AI-driven drug discovery
  company founded in 2019 by Thomas Miller (CEO) and Fred Manby (CTO) that
  designs small-molecule therapeutics for oncology and other indications.
  Iambic builds proprietary AI models for drug discovery, including Enchant,
  a multimodal transformer that predicts clinical properties (pharmacokinetics,
  cellular and biochemical activity) of candidate molecules from early
  discovery data, and NeuralPLexer (now NeuralPLexer3), a flow-based
  generative model for protein-ligand complex structure prediction used to
  identify cryptic pockets and guide structure-based design. Both lines of
  work have been published at venues including NeurIPS 2025. The company's
  internal pipeline is oncology-led: IAM1363, a brain-penetrant selective
  HER2 / HER2-mutant inhibitor, completed Phase 1/1b dose escalation in 2025
  and is in dose optimization with clinical activity reported at ESMO 2025;
  IAM-K1 (KIF18A) and IAM-C1 (CDK2/4) are preclinical, alongside
  undisclosed neurology, gastrointestinal, and inflammation discovery
  programs. In February 2026 Iambic announced a discovery and technology
  collaboration with Takeda worth up to ~$1.7B plus royalties, following a
  $100M+ private financing in November 2025 and total disclosed funding of
  approximately $334M. The company has been named to the CNBC Disruptor 50
  list in 2025 and 2026 and has signaled intent to access public markets,
  including via a SPAC. Iambic's public GitHub footprint is limited to
  np-bench, a BSD-3 benchmark library for 3D biomolecular structure
  prediction; the underlying NeuralPLexer and Enchant models are proprietary
  and there is no public developer API, SDK, or commercial platform offering.
type: Index
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/apis-json-logo.jpg
tags:
  - AI Drug Discovery
  - Drug Discovery
  - Therapeutics
  - Oncology
  - Small Molecules
  - HER2
  - KIF18A
  - CDK2 CDK4
  - Multimodal Transformers
  - Structure Prediction
  - Protein Ligand
  - Enchant
  - NeuralPLexer
  - Biotech
  - San Diego
url: https://raw.githubusercontent.com/api-evangelist/iambic-tx/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
  - type: DomainSecurity
    url: security/iambic-tx-domain-security.yml
  - type: Website
    url: https://www.iambic.ai
  - type: Platform
    url: https://www.iambic.ai/platform
  - type: Pipeline
    url: https://www.iambic.ai/pipeline
  - type: Partners
    url: https://www.iambic.ai/partners
  - type: About
    url: https://www.iambic.ai/about
  - type: News
    url: https://www.iambic.ai/news
  - type: Careers
    url: https://www.iambic.ai/careers
  - type: Contact
    url: https://www.iambic.ai/contact
  - type: Enchant
    url: https://www.iambic.ai/post/enchant-announcement
  - type: EnchantV2
    url: https://www.iambic.ai/post/iambic-announces-enchant-v2-its-next-generation-ai-model-for-predicting-the-clinical-viability-of-drug-discovery-programs
  - type: NeuralPLexer
    url: https://www.iambic.ai/post/neuralplexer
  - type: TakedaCollaboration
    url: https://www.iambic.ai/post/iambic-announces-collaboration-with-takeda
  - type: IAM1363ESMO
    url: https://www.iambic.ai/post/esmo-iam1363
  - type: IAM1363DoseEscalation
    url: https://www.iambic.ai/post/dose-escalation
  - type: GitHub
    url: https://github.com/iambic-therapeutics
  - type: NPBench
    url: https://github.com/iambic-therapeutics/np-bench
  - type: LinkedIn
    url: https://www.linkedin.com/company/iambic-therapeutics
  - url: https://www.iambic.ai/news
    type: Blog
maintainers:
  - FN: Kin Lane
    email: kin@apievangelist.com